Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Public ClinicalTrials.gov record NCT04514484. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
Study identification
- NCT ID
- NCT04514484
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 8 participants
Conditions and interventions
Conditions
- Advanced Differentiated Thyroid Gland Carcinoma
- Advanced Head and Neck Carcinoma
- Advanced Hepatocellular Carcinoma
- Advanced Kaposi Sarcoma
- Advanced Lung Non-Small Cell Carcinoma
- Advanced Lung Small Cell Carcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Melanoma
- Advanced Ovarian Carcinoma
- Advanced Prostate Carcinoma
- Advanced Renal Cell Carcinoma
- Advanced Thyroid Gland Medullary Carcinoma
- Advanced Triple-Negative Breast Carcinoma
- Advanced Urothelial Carcinoma
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Castration-Resistant Prostate Carcinoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- HIV Infection
- Metastatic Differentiated Thyroid Gland Carcinoma
- Metastatic Head and Neck Carcinoma
- Metastatic Hepatocellular Carcinoma
- Metastatic Kaposi Sarcoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Lung Small Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Metastatic Ovarian Carcinoma
- Metastatic Prostate Carcinoma
- Metastatic Renal Cell Carcinoma
- Metastatic Thyroid Gland Medullary Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Metastatic Urothelial Carcinoma
- Recurrent Differentiated Thyroid Gland Carcinoma
- Recurrent Head and Neck Carcinoma
- Recurrent Hepatocellular Carcinoma
- Recurrent Kaposi Sarcoma
- Recurrent Lung Non-Small Cell Carcinoma
- Recurrent Lung Small Cell Carcinoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Melanoma
- Recurrent Ovarian Carcinoma
- Recurrent Prostate Carcinoma
- Recurrent Renal Cell Carcinoma
- Recurrent Thyroid Gland Medullary Carcinoma
- Recurrent Triple-Negative Breast Carcinoma
- Recurrent Urothelial Carcinoma
- Refractory Differentiated Thyroid Gland Carcinoma
- Stage III Differentiated Thyroid Gland Carcinoma AJCC v8
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage III Thyroid Gland Medullary Carcinoma AJCC v8
- Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
Interventions
- Biospecimen Collection Procedure
- Cabozantinib S-malate Drug
- Computed Tomography Procedure
- Magnetic Resonance Imaging Procedure
- Nivolumab Biological
Procedure · Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 21, 2021
- Primary completion
- Nov 10, 2024
- Completion
- Feb 5, 2027
- Last update posted
- Mar 22, 2026
2021 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwestern University | Chicago | Illinois | 60611 | — |
| Montefiore Medical Center-Einstein Campus | The Bronx | New York | 10461 | — |
| University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania | 15232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04514484, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04514484 live on ClinicalTrials.gov.